Anti-Infective Clinical Trials
|
|
- Anne Bryan
- 6 years ago
- Views:
Transcription
1 Anti-Infective Clinical Trials
2 The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting anti-infective clinical trials. In addition to our state-of-the-art technology, we provide global support and best practice/standard of care information during study set-up and advise and interact with our clients throughout the course of the clinical trial. Through a collaborative partnership we enhance and expedite quality delivery of accurate data that ultimately leads to the approval of new drugs which save lives and improve quality of life. Bacteriology, Parasitology & Mycology Clinical development programmes for anti-microbial compounds are becoming increasingly complex and necessitate a unique level of central laboratory support. As a global central laboratory dedicated exclusively to clinical trials, within the past 4 years we have supported over 90 bacteriology, parasitology and mycology studies ranging from Phase I to Phase IV, across 30 different disease indications, receiving study visits from in excess of 25,000 subjects. Our in-house capabilities in the US, Europe and Asia enable us to provide global consistency and quality data across all countries involved in your study. Excellence in Microbiology (EIM) Committee ICON has brought together world class experts with a combined 160 years of microbiology experience to create a committee dedicated to ensuring the success of your trial. Our EIM collaborates with your scientists to ensure the most appropriate protocol design and best in class analytical methods are chosen for your study. They will partner with your team from pre-award right through to database lock to ensure quality, timely and accurate result reporting and data transfers, in addition to providing ongoing expertise, advice and innovative solutions, to enable better, faster decision making. Review & discuss new protocols Review standard Advise and consider best practice Review & approve client specific Discuss global quality performance Review standard methods Collaboration with 3rd party laboratories Capabilities Culture, Identification & Susceptibility Customised MICs Testing all specimen types & isolates Semi-Quantitative &Quantitative cultures Species level identification Anaerobic chambers for culture & susceptibility tests Long term storage Custom assay transfer & validation Identification Systems Vitek Compact 2 API Conventional tests Spot Tests Special Stains Antibody & Antigen detection Operational Parameters 4-5 days TAT for a simple culture 6 days per week sample processing 7 day coverage for culture & susceptibility testing CLSI guidelines used (QC review, interpretation, result analysis) 20 day MIC validation for new studies Experience working with local & regional labs
3 Bacteriology, Parasitology & Mycology Customised Solutions Virology Tests, platforms, capabilities Virology EIM reviews all protocols Understanding of Microbiology testing regulatory requirements Extensive Microbiology expertise to optimise study design Ongoing availability of experts for consultation and support Viral loads are critical for assessing on-treatment anti-viral activity and treatment efficacy for anti-viral clinical trial programs. With so much importance placed on these data, it s critical that the central laboratory chosen to support your program has extensive experience and expertise in this field. In the past 4 years, ICON has successfully supported over 100 anti-viral studies across 14 disease indications, ranging from Phase I to Phase IV. We have received and tested samples from over 20,000 subjects at our global facilities from 42 countries worldwide. EIM and Client Collaboration ICON Technical Committee (ATC) Molecular Experts Precludes the need for additional testing Reduce time and financial wastage post regulatory submission Custom made procedure for testing to ensure regulatory and client specific requirements are met MIC panels are customised ICON s ITC brings together over 150 years of practical experience in collaborating with clients from protocol review right through to database lock. Our experts will advise on the benefits of specific assay utilization, protocol design and in-house custom assay transfers throughout the lifecycle of your anti-viral programme. Capabilities & Methodologies Testing Platforms Assays Include: Operational Parameters Real-time quantitative PCR Real-time qualitative PCR Reverse Transcription PCR Genotyping High speed automated immunoassays Manual EIAs Molecular Testing Abbott Diagnostics M2000 Roche Diagnostics COBAS TaqMan 48 Roche Diagnostics COBAS AmpliPrep/TaqMan Autoblot 3000H Immunoassays HIV 1&2 Ag/Ab CMIA Screen Hep A Ab IgM & Total Hep B Core Ab IgM & Total Hep B Surface Ab, Qualitative & Quantitative Hep B Surface Ag Qualitative & Quantitative Hep Be Antigen & Antibody Hep C Ab Screen CMV Ab EBV Ab Cellular Immunology Multi-colour Flow Cytometry CD4+ T Helper Cell quantitation Immunophenotyping (Lymphocyte subsets) Activation Markers Intracellular Cytokine Detection HBV Viral load HCV Qualitative HCV Viral Load HIV-1 Viral load CMV Viral load EBV Viral Load HBV Genotype HCV Genotype Abbott Diagnostics ARCHITECT i2000sr Ortho Clinical Diagnostics VITROS ECi Molecular Devices SpectraMax BD FACSCanto II BD FACSCalibur Consistency across testing locations Global SOPs EQA Interlab comparison Delta checks for false ve and false +ve results Contamination preventive measures Highly specific analytical methods to counter variation at genetic level Reflex evaluations Experience managing method to method differences between local/ regional labs and a central lab Innovative Data Solutions for Anti-virals ICONIK Hepatitis Package To assist in the rapid assessment and evaluation of the large volume of data generated during an anti-viral study, ICON have created an innovative data analytics package that is specifically designed to visually display the drug response of subjects as they progress through the treatment and post-treatment phases of hepatitis studies. Data can be stratified by genotype, liver function test results, countries, sites and multiple other subject parameters, and is available on an ongoing basis throughout the course of the study. Data can also be analysed at a program level, to rapidly visualize large data sets combined across protocols.
4 Virology Custom Flow Cytometry We have a dedicated Research and Development team who bring together over 100 years of experience in successfully developing and validating high complexity cell-based assays--from in-vitro diagnostic methods to fully customised, multi-parametric biomarker panels. Our global flow cytometry operations team executes these assays in our harmonised central labs around the world using state-of-the-art, standardised instrumentation; delivering consistent, timely high-quality results to inform your anti-viral programmes. Support Services In addition to the extensive anti-infective test menu, experience and expertise you ll find at ICON, we provide all of the necessary additional support services to ensure the successful execution of your clinical trial Safety and Supplementary Testing Logistics Data Management Project Management Site Support Study Materials and Instructional Support Quality Assurance Pre Optional (Sponsor-specific high complexity assays) 1 Week Transfer Receipt of project specific materials Performance of method transfer assays Review of results, additional actions Plan creation QC of plan Approval Performance of studies Data review, discussion with developer Additional studies if necessary Transfer Plan Creation Experments 2 Weeks 5-2 Weeks 4-8 Weeks Why ICON For Anti-Infectives Our state of the art technology, scientific expertise, experience and global reach make ICON the ideal partner for your anti-infective drug development program. Our scientific staff have authored or co-authored over 120 publications in peer reviewed journals, as well as serving on the committees of renowned anti-infective organisations and journals. Our dedicated support teams of Project Managers, Logistics Experts, Data Management teams, Quality Assurance and Site Support Personnel ensure that every aspect of your study is managed to the highest level of quality and satisfaction. Come and talk to us to find out more about what we can offer you. For more information contact: enquiries@iconplc.com ICONplc.com/labs Creation of draft QC, creation of final version Approval of validation report Report creation 4 Weeks Training Global Method Rollout
5 ICON plc Corporate Headquarters South County Business Park Leopardstown, Dublin 18 Ireland T: F: info@iconplc.com ICONplc.com/labs
WHO Prequalification of In Vitro Diagnostics Programme
WHO Prequalification of In Vitro Diagnostics Programme International HIV/Viral Hepatitis Co-Infection Satellite Meeting 19 July 2014, Melbourne Anita Sands Prequalification Diagnostics Team Department
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationCleveland Clinic Laboratories. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Trust in us for everything you need in a reference lab. 2 Cleveland Clinic Laboratories At Cleveland Clinic Laboratories, we recognize the results we turn out are pivotal
More informationNATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal
NATIONAL STANDARD METHODS: ASSURING QUALITY IN UK Portugal Valerie Bevan Department for Evaluations and Standards Laboratory Centre for Infections Health Protection Agency October 2008 Structure of talk
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationFifteen years of molecular EQA: progress and challenges
Fifteen years of molecular EQA: progress and challenges Anton M van Loon 1, Stuart West 2 and Paul Wallace 2 1 Department of Virology, UMC Utrecht, The Netherlands 2 QCMD, Glasgow, Scotland Key Issues
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationThe use of QCMD proficiency testing panels in clinical virology.
The use of QCMD proficiency testing panels in clinical virology. Prof.dr. Bert Niesters Department of Medical Microbiology Division of Clinical Virology UMC Groningen Disease Disease Management Viral Load
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationNAT / BLOOD SCREENING - PRODUCT RANGE
NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio
More informationBEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis (CTDNA11A) William G Mackay on behalf of QCMD and its Scientific Council April 2011 Not to be reproduced or quoted without permission of QCMD.
More informationOverview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationResearch Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests
IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision
More informationDocumentation, Codebook, and Frequencies
2 Documentation, Codebook, and Frequencies Laboratory Component: Hepatitis B: core antibody, surface antibody and surface antigen; Hepatitis C: confirmed antibody; Hepatitis D antibody Survey Years: 2003
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationPlease describe the laboratory facilities available in your research institute, including the items listed below (if applicable):
Institution: Instituto Nacional de Saúde (INS) [National Institute of Health Mozambique] Maputo, Mozambique Contact: Edna Viegas Medical Doctor edna_viegas@hotmail.com LAB RESOURCES Please describe the
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK West of Scotland Specialist Virology Centre New Lister Building Level 5 Glasgow Royal Infirmary 10-16 Alexandra Parade Glasgow G31 2ER Contact:
More informationMP Biomedicals Asia Pacific Pte. Ltd. (formerly Genelabs Diagnostics Pte. Ltd.)
Revision: 12 May 2005 1 WESTERN BLOT / IMMUNOBLOT HIV-1 BLOT Version 1.3* 11010-018 HIV-1 viral lysate Western Blot assay for the 11010-036 detection of antibodies to HIV-1 with serum 11010-108 108 strips
More informationNational Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016
Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager
More informationUnited Kingdom National External Quality Assessment Service for Microbiology [Established 1971]
United Kingdom National External Quality Assessment Service for Microbiology [Established 97] UK NEQAS covers Andrology Chemistry Genetics Haematology Histopathology Immunology Leucocyte Immunophenotyping
More informationUnderstanding Quality Control for Infectious Disease Testing. Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018
Understanding Quality Control for Infectious Disease Testing Wayne Dimech ASLM Quality Control Workshop Abuja, Nigeria 9 th December 2018 Disclosure Attendance at ASLM part-sponsored by CDC No personal
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationJefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014
Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationSchedule of Accreditation
Schedule of Accreditation Organisation Name National Virus Reference Laboratory INAB Reg No 326MT Contact Name Eimear Malone Address University College Dublin, Belfield, Dublin Contact Phone No 01-7161319
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationRobert G. Gish MD UC San Diego
Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationSP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationHIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26
1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationMultichem Infectious Disease QC
Infectious Disease QC Contents Introduction....3 Quality Control in the Laboratory...4 Infectious Disease (ID) QC....5 Ready-to-use Concept....6 NRL...7 QConnect...8 IAMQC in Collaboration with QConnect....
More informationThe testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
More informationMass Spectrometry Made Simple for Clinical Diagnostic Labs
Mass Spectrometry Made Simple for Clinical Diagnostic Labs The SCIEX Topaz System with FDA-Cleared Topaz Vitamin D 200M Assay Kit Mass Spectrometry Made Simple SCIEX Topaz System for Clinical Diagnostics
More informationCleveland Clinic Laboratories Hematology Diagnostic Services. Trust in us for everything you need in a reference lab.
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationEvaluation of the new Abbott mplus feature: Impact on clinical laboratory efficiencies with Abbott RealTime HIV-1, HCV, HBV and CT/NG assays
JCM Accepts, published online ahead of print on 2 October 2013 J. Clin. Microbiol. doi:10.1128/jcm.01672-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 Evaluation
More informationQUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment William G MacKay PhD Neutral Office Coordinator QCMD The Altum Building, Todd Campus
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Luton and Dunstable University Hospital NHS Foundation Trust Lewsey Road Luton Bedfordshire LU4 0DZ Contact: Pauline Philip Tel: +44 (0)1582
More informationGLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE
GLOBAL ANTIMICROBIAL RESISTANCE SURVEILLANCE Sonja Löfmark Public Health Agency of Sweden 6 th BARN Workshop May 12, 2016 Uppsala What is GLASS? A global programme for AMR surveillance The data it collects
More informationFINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Mar/11 HBV Serology EQAS Panel ID 2008/Mar/11 Page 1 of 9 The NRL is a: NATA-accredited proficiency
More informationHepatitis C Virus (RNA)A
Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationEconomic Value Lab Efficiencies Safety Clinical Outcomes. Visit BD Booth AACC/ASCLS 2009 Annual Meeting
Economic Value Lab Efficiencies Safety Clinical Outcomes Visit BD Booth 1225 AACC/ASCLS 2009 Annual Meeting BD Events & Co-Promotions Join us this year at booth #1225 to discover the full spectrum of solutions
More informationCEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE
CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE TITLE : SOP for (off board dilution) Less Sensitive Modified VITROS Enzyme Immunoassay CEPHIA DOCUMENT
More informationUpdate from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012
Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationWHO Guidelines on hepatitis B and C testing
WHO Guidelines on hepatitis B and C testing Dr. Philippa Easterbrook Global Hepatitis Programme World Hepatitis Summit Nov 2017 Sao Paulo, Brazil Outline of presentation Key recommendations of 2017 WHO
More informationPrimary Sample Manual Infectious Serology Issue No Effective Date: 20/09/17 Page 1 of 15 EUROFINS BIOMNIS
Issue No. 2.02 Effective Date: 20/09/17 Page 1 of 15 Written / Revised By: Dr. Mike Louw, Medical Director Date: Reviewed By: Date: Dr. Sinead Kelly, Infectious Serology Consultant Authorised By: Jean-Sébastien
More informationHELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT
HELPING DELIVER LIFE-CHANGING THERAPIES VACCINE DEVELOPMENT PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT With more than 25 years of vaccine development experience for both government and
More informationAnswering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa
Answering your daily challenges in the ELISA technology I N FECTI OUS DISEASES bioelisa RETROVIRUS HIV is the cause of the most important global pandemic. Due to the lack of vaccination, early diagnosis
More informationWHO recommendations. Diagnostic testing in infants
WHO recommendations Diagnostic testing in infants Recommendations 2- testing in infants Intervention Reco QoE Comment At or around 6 weeks of age is most efficient time at which to perform a viral test
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationAdvantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationMemo No: Date: 25-Nov NEW Serology and Virology Testing
Memo No: 2014-61 Date: 25-Nov-2014 www.hicl.on.ca Re: NEW Serology and Virology Testing In Common Laboratories has been working hard to expand our test menu. We are pleased to announce the availability
More informationNew Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility Gerald A. Capraro, Ph.D., D(ABMM) Director, Clinical Microbiology Carolinas Pathology Group Atrium
More informationLaboratory Strengthening Gloria Young BD Biosciences
Laboratory Strengthening y g g Gloria Young BD Biosciences Lessons Learned from Establishing CD4 Testing Capability in Resource-Limited Countries Background Why Lab Strengthening BD s experience What works
More information4.9. Monitoring treatment response HCV Decision-making tables PICO 9
4.9. Monitoring treatment response HCV Decision-making tables PICO 9 Monitoring for treatment response using HCV Ag testing in individuals with confirmed active HCV infection: Among individuals receiving
More informationEvolutionary Outsourcing Model: Delivering Solutions through Partnership. Tammy Harter and Tony Parry Clinical Bioanalysis Alliance (CBioA)
Evolutionary Outsourcing Model: Delivering Solutions through Partnership Tammy Harter and Tony Parry Clinical Bioanalysis Alliance (CBioA) Introduction Pre Alliance Years History Drivers for change The
More informationOur T cell epitope test service offers you:
Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationUK Standards for Microbiology Investigations
UK Standards for Microbiology Investigations Blood Borne Virus Testing in Dialysis Patients Issued by the Standards Unit, Microbiology Services, PHE Virology V 10 Issue no: 2 Issue date: 27.04.15 Page:
More informationHIV immunological and virological monitoring tools. Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011
HIV immunological and virological monitoring tools Pascale Ondoa 5th INTEREST workshop Dar es Salam Thursday 12th, 2011 Monitoring HIV disease progression and treatment When to start ART? CD4 count When
More informationPoint of care, near patient testing, of blood borne viruses issues with design and implementation of programs
Point of care, near patient testing, of blood borne viruses issues with design and implementation of programs Philip Cunningham Conjoint Associate Professor (UNSW) NSW State Reference Laboratory for HIV
More informationIl ruolo delle VEQ per la sicurezza trasfusionale
Il ruolo delle VEQ per la sicurezza trasfusionale The role of EQA for transfusion safety Giulio Pisani CNCF Ist. Sup. Sanità Global Blood Product Safety, Roma 10 aprile 2019 Blood transfusion is an essential
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationAssociate Professor, HIV Focal Person, KBTH
Institution: University of Ghana Medical School Korle Bu Teaching Hospital (KBTH) Accra, Ghana Contact: Margaret Lartey Associate Professor, HIV Focal Person, KBTH malart38@yahoo.com LAB RESOURCES Please
More informationConsolidated Donor Funded Procurement of HIV Diagnostics
Consolidated Donor Funded Procurement of HIV Diagnostics Meeting on HIV Diagnostic Global Demand Forecast Geneva, 9 April 2015 Mercedes Perez Gonzalez Prequalification Team Diagnostics Assessment Department
More information4.5. How to test - testing strategy HBV Decision-making tables PICO 3
World Health Organization Global Hepatitis Programme 4.5. How to test - testing strategy HBV Decision-making tables PICO 3 Testing strategy to diagnose chronic HBV infection through detection of HBsAg:
More informationAgenda Part I: Overview of implementation of POC technologies Global Pan Canadian Regional-Quebec Part II: In-view CIHR funded Evidence syntheses HIV
Point--of Point of--care (POC) for HIV and related coco-infections: Quo vadis? Nitika Pant Pai, MD., MPH., PhD Assistant Professor Division of Infectious Disease Division of Clinical Epidemiology Department
More informationA Strategic Roadmap for the PICARD Programme in 2020
A Strategic Roadmap for the PICARD Programme in 2020 DRAFT 1. Background Since the launch of the WCO Partnership In Customs Academic Research and Development (PICARD) Programme in 2006, its two objectives
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationQuality Assurance Policy. for the. Procurement of HIV Point-of-Care Technology. under the UNITAID Grant
Quality Assurance Policy for the Procurement of HIV Point-of-Care Technology under the UNITAID Grant UNICEF Supply Division Quality Assurance Centre and Health Technology Centre Revisions Version Date
More informationNRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens
NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping
More informationSample Selection, Collection, Transport: Issues & Challenges
Sample Selection, Collection, Transport: Issues & Challenges Jim Dunn, PhD, D(ABMM) Director, Medical Microbiology and Virology Texas Children s Hospital LEARNING OBJECTIVES 1. Identify factors to consider
More informationBEIPH Final Report. QCMD 2009 Neisseria gonorrhoeae (NGDNA09) EQA Programme
QUALITY CONTROL for MOLECULAR DIAGNOSTICS Block 4, Kelvin Campus, West of Scotland Science Park, Glasgow, G20 0SP Scotland Tel: +44 (0) 141 945 6474 Fax: +44 (0) 141 945 5795 www.qcmd.org info@qcmd.org
More informationMonitoring results: goals, strategic objectives and indicators
page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator
More informationQuality Management System Certification. Understanding Quality Management System (QMS) certification
Quality Management System Certification Understanding Quality Management System (QMS) certification The medical device manufacturing sector is one of the most regulated sectors in which significant quality
More informationFINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Oct/28 HBV Serology EQAS Panel ID 2008/Oct/28 Page 1 of 11 The NRL is a: NATA-accredited proficiency
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More information4.6. How to test - testing strategy HCV. Decision-making tables PICO 4
4.6. How to test - testing strategy HCV Decision-making tables PICO 4 Testing strategy to ascertain exposure to HCV: Among persons identified for hepatitis C testing, what is the best testing strategy
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationRapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012
Rapid Diagnostics CHAI Experience 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012 CHAI is working in 12 countries on HIV POC test implementation Kenya Tanzania Ethiopia Malawi Mozambique
More informationInstructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^
Page 1 of 5 Page 1 of 5, 97/656 WHO 1 st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) NIBSC code: 97/656 Instructions for Use (Version 3-14 th May 2003) Changes from previous
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationINTEGRATING HIV AND HCV TESTING
INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access
More informationRadiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions
Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment
More informationASCO Power Control Systems Overview
ASCO Power Control Systems Overview POWER CONTROL CHALLENGES Today more than ever, continuous electrical power is essential for providing mission-critical services. Whether it s a hospital providing critical
More informationDiagnosis of infectious diseases and confirmation of diagnosis. Molecular epidemiology of emerging/re-emerging pathogens
LA PREPARAZIONE E LA RISPOSTA ALLE EMERGENZE INFETTIVE Padova, 20 settembre 2012 Laboratory advanced technologies in the support of Public Health interventions in infectious disease emergencies Prof. Giorgio
More informationUpdate on WHO Prequalification of In Vitro Diagnostics
Update on WHO Prequalification of In Vitro Diagnostics Robyn Meurant and Mercedes Perez Gonzalez Prequalification Team Diagnostics Assessment Essential Medicines and Health Products World Health Organization
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation Drug Delivery Systems: It s in the detail
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation 3M is a global innovation company that
More informationUnderstanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
More informationBEIPH Final Report. EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011
BEIPH Final Report EQA Programme 2011 Chlamydia trachomatis B (CTDNA11B) Prepared on behalf of QCMD and its Scientific Council October 2011 Not to be reproduced or quoted without permission of QCMD. Any
More information